Back to resultsEfficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis (ESCAPE-NEXT)
Primary Purpose
Stroke, Acute
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Placebo
Nerinetide
Sponsored by
About this trial
This is an interventional treatment trial for Stroke, Acute
Eligibility Criteria
Inclusion Criteria:
- Acute ischemic stroke (AIS) selected for emergency endovascular treatment.
- Age 18 years or greater.
- Onset (last-known-well) time to randomization time within 12 hours.
Disabling stroke defined as a baseline National Institutes of Health Stroke Score (NIHSS):
- NIHSS > 5 for internal carotid artery (ICA) and M1-middle cerebral artery (MCA) occlusion; or
- NIHSS > 10 for M2-MCA occlusion.
- Confirmed symptomatic intracranial occlusion at one or more of the following locations: Intracranial carotid I/T/L, M1 or M2 segment MCA. Tandem extracranial carotid and intracranial occlusions are permitted.
- Pre-stroke (24 hours prior to stroke onset) independent functional status in activities of daily living with modified Barthel Index (BI) ≥ 95. Patient must be living without requiring nursing care.
- Qualifying imaging performed less than 2 hours prior to randomization.
- Consent process completed as per national laws and regulation and the applicable ethics committee requirements.
Exclusion Criteria:
- Treated with a tissue plasminogen activator (e.g., alteplase or tenecteplase) within 24 hours before randomization.
- Determination by the treating physician, based on current treatment guidelines and medical evidence, that treatment with a plasminogen activator is indicated.
- Large core of established infarction defined as ASPECTS 0-4.
- Absent or poor collateral circulation on qualifying imaging (e.g. collateral score of 0 or 1).
- Any intracranial hemorrhage on the qualifying imaging.
- Planned use of an endovascular device not having approval or clearance by the relevant regulatory authority.
- Endovascular thrombectomy procedure is completed as defined by the presence of TICI 2c/3 reperfusion or completion of groin / arterial closure.
- Clinical history, past imaging or clinical judgment suggesting that the intracranial occlusion is chronic or there is suspected intracranial dissection such that there is a predicted lack of success with endovascular intervention.
- Estimated or known weight > 120 kg (264 lbs).
- Pregnancy/Lactation; female, with positive urine or serum beta human chorionic gonadotropin (β-hCG) test, or breastfeeding.
- Known prior receipt of nerinetide for any reason, including prior enrolment in this ESCAPE-NEXT trial.
- Severe known renal impairment defined as requiring renal replacement therapy (hemo- or peritoneal dialysis).
- Severe or fatal comorbid illness that will prevent improvement or follow up.
- Inability to complete follow-up treatment to Day 90.
- Participation in another clinical trial investigating a drug, medical device, or a medical procedure in the 30 days preceding trial inclusion.
Sites / Locations
- St. Joseph's Hospital & Medical Center
- Providence Little Company of Mary Medical Center - Torrance
- Swedish Medical Center
- Baptist Health Research Institute
- University of Miami, Jackson Memorial Hospital
- Grady Memorial Hospital
- University of Maryland Medical Center
- University of Massachusetts Medical School
- Montefiore Medical Center
- NYU Langone Hospital Brooklyn
- The Ohio State University, Wexner Medical Center Neurological Surgery
- Providence St. Vincent Medical Center
- Abington Memorial Hospital
- UPMC Stroke Institute
- Rhode Island Hospital
- Valley Baptist Medical Center - Harlingen
- Swedish Medical Center - Cherry Hill Campus
- Royal Adelaide Hospital
- Princess Alexandra Hospital
- Monash Medical Centre
- Gold Coast University Hospital
- Fiona Stanley Hospital
- Sir Charles Gairdner Hospital
- John Hunter Hospital
- Royal Melbourne Hospital
- Foothills Medical Centre - University of Calgary
- University of Alberta Hospital
- Vancouver General Hospital
- Health Sciences Centre
- Queen Elizabeth II Health Science Centre
- Hamilton Health Sciences
- Kingston Health Sciences Centre
- London Health Sciences Centre (LHSC)
- Ottawa Hospital Research Institute (OHRI)
- St. Michael's Hospital, Unity Health Toronto
- Sunnybrook Health Science Centre
- Toronto Western Hospital
- Montreal Neurological Institute and Hospital
- University Hospital of Montreal
- CHU de Quebec-Universite Laval
- Royal University Hospital
- Universitätsklinikum RWTH Aachen
- Klinikum Altenburger Land GmbH
- Universitätsklinikum Augsburg
- Universitätsklinikum Knappschaftskrankenhaus Bochum
- Universitätsklinikum Bonn
- Klinikum Dortmund gGmbH
- University of Dresden
- Alfried-Krupp-Krankenhaus
- Universitätsklinikum Frankfurt
- Universitätsklinikum Freiburg
- Göttingen University Hospital
- Universitätsklinikum Hamburg-Eppendorf
- Heidelberg University Hospital
- University Hospital Schleswig-Holstein
- Universitätsklinikum Leipzig - Klinik und Poliklinik für Neurologie
- Klinikum rechts der Isar Technical University of Munich
- LMU Klinikum München
- Universitätsklinikum Münster
- Nürnberg Hospital South Campus
- Evangelisches Krankenhaus Oldenburg
- Klinikum Stuttgart
- Universitätsklinikum Tübingen
- Würzburg University Hospital
- Ospedale Maggiore di Bologna "Carlo Alberto Pizzardi"
- Azienda Ospedaliero Universitaria Careggi
- Ospedale Policlinico San Martino
- ASST Grande Ospedale Metropolitano Niguarda
- Azienda Ospedaliera Antonio Cardarelli
- Amsterdam UMC
- Maastricht University Medical Center
- Erasmus University Medical Center
- Oslo University Hospital Rikshospitalet
- Oslo University Hospital Ulleval
- Stavanger University Hospital
- University Hospital of North-Norway
- National Neuroscience Institute
- National University Hospital
- Kantonsspital Aarau
- Universitätsspital Basel
- Universitatsklinik fur Neurologie, Inselspital
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Experimental
Arm Label
Placebo
Nerinetide
Arm Description
Vehicle only
Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
Outcomes
Primary Outcome Measures
Number of participants with independent functioning on the modified Rankin Scale (mRS), as defined by a score of 0-2
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.
Secondary Outcome Measures
Mortality rate, as defined by event rate (percent) for mortality over the 90-day study period.
Number of participants exhibiting a worsening of their index stroke.
Worsening of stroke is defined as (A) progression, or hemorrhagic transformation of the index stroke, as documented by medical imaging that is (a) life-threatening requiring intervention and/or (b) results in increased disability as gauged by a ≥4 point increase from lowest NIHSS during hospitalization or (B) results in death from the index stroke.
A shift of one or more categories to reduced functional dependence analyzed across the whole distribution of outcomes on the mRS at Day 90 post randomization.
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.
Number of participants with good neurological outcome, as defined by a score of 0-2 on the NIHSS at Day 90 post randomization.
The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination score that is a valid and reliable measure of disability and recovery after acute stroke. Scores range from 0 to 42, with higher scores indicating increasing severity.
Full Information
NCT ID
NCT04462536
First Posted
July 2, 2020
Last Updated
September 8, 2023
Sponsor
NoNO Inc.
Collaborators
University of Calgary
1. Study Identification
Unique Protocol Identification Number
NCT04462536
Brief Title
Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
Acronym
ESCAPE-NEXT
Official Title
A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
December 6, 2020 (Actual)
Primary Completion Date
August 31, 2023 (Actual)
Study Completion Date
August 31, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NoNO Inc.
Collaborators
University of Calgary
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The primary purpose of this study is to determine if a single dose of nerinetide can reduce global disability in people who have had a stroke and are selected for endovascular therapy without the use of a tissue plasminogen activator (alteplase, tenecteplase, or equivalent).
Detailed Description
This study is a Phase 3, randomized, multicentre, blinded, placebo-controlled, parallel group, single-dose with a single interim analysis. Because AIS (acute ischemic stroke) is a medical emergency, the trial is designed to enable the administration of standard-of-care treatments without delay in order to save the life of the person concerned, restore good health or alleviate suffering.
Participants harboring an acute ischemic stroke who are selected for endovascular revascularization without intravenous or intra-arterial thrombolytic therapy will be given a single, 2.6 mg/kg (up to a maximum dose of 270 mg) intravenous dose of nerinetide or placebo. Outcomes of the main trial will be evaluated throughout a 90 day observation period.
Participants will be followed at 1-Year for the analytic sub-trial for further outcome assessment by telemedicine or telephone interview conducted by individuals blinded to the outcome of the main trial. This sub-trial will be conducted to explore the independent functioning and quality of life at 1-Year.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Acute
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
850 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Vehicle only
Arm Title
Nerinetide
Arm Type
Experimental
Arm Description
Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Vehicle only
Intervention Type
Drug
Intervention Name(s)
Nerinetide
Other Intervention Name(s)
NA-1
Intervention Description
Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
Primary Outcome Measure Information:
Title
Number of participants with independent functioning on the modified Rankin Scale (mRS), as defined by a score of 0-2
Description
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Mortality rate, as defined by event rate (percent) for mortality over the 90-day study period.
Time Frame
90 days
Title
Number of participants exhibiting a worsening of their index stroke.
Description
Worsening of stroke is defined as (A) progression, or hemorrhagic transformation of the index stroke, as documented by medical imaging that is (a) life-threatening requiring intervention and/or (b) results in increased disability as gauged by a ≥4 point increase from lowest NIHSS during hospitalization or (B) results in death from the index stroke.
Time Frame
90 days
Title
A shift of one or more categories to reduced functional dependence analyzed across the whole distribution of outcomes on the mRS at Day 90 post randomization.
Description
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.
Time Frame
90 days
Title
Number of participants with good neurological outcome, as defined by a score of 0-2 on the NIHSS at Day 90 post randomization.
Description
The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination score that is a valid and reliable measure of disability and recovery after acute stroke. Scores range from 0 to 42, with higher scores indicating increasing severity.
Time Frame
90 days
Other Pre-specified Outcome Measures:
Title
Volume of stroke as measured by MRI or CT brain imaging (MRI preferred)
Time Frame
90 days
Title
Number of participants with functional independence in activities of daily living, as defined by a score of ≥ 95 on the Barthel Index (BI) at Day 90 post randomization.
Description
The BI is an index of functional independence that is a valid measure of activities of daily living when employed in stroke trials. Modified BI scores range from 0 to 100, with higher scores indicating greater independence in activities of daily living and mobility.
Time Frame
90 days
Title
Number of participants with reduced moderate or severe disability or death, as defined by a score of 4-6 on the mRS at Day 90 post randomization.
Description
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.
Time Frame
90 days
Title
Number of participants with excellent functional outcome, as defined by a score of 0-1 on the mRS at Day 90 post randomization.
Description
The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.
Time Frame
90 days
Title
Health-related quality of life, as measured by the EQ-5D-5L at Day 90.
Description
The EQ-5D-5L (EuroQol 5-Dimensional 5-Level) is a generic instrument for describing and valuing health. It is based on a descriptive system that defines health in terms of five dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has five response categories corresponding to: no problems, slight, moderate, severe and extreme problems. The respondents will also rate their overall health on the day of the interview on a 0-100 visual analogue scale (EQ-VAS, higher scores mean better outcomes).
Time Frame
90 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Acute ischemic stroke (AIS) selected for emergency endovascular treatment.
Age 18 years or greater.
Onset (last-known-well) time to randomization time within 12 hours.
Disabling stroke defined as a baseline National Institutes of Health Stroke Score (NIHSS):
NIHSS > 5 for internal carotid artery (ICA) and M1-middle cerebral artery (MCA) occlusion; or
NIHSS > 10 for M2-MCA occlusion.
Confirmed symptomatic intracranial occlusion at one or more of the following locations: Intracranial carotid I/T/L, M1 or M2 segment MCA. Tandem extracranial carotid and intracranial occlusions are permitted.
Pre-stroke (24 hours prior to stroke onset) independent functional status in activities of daily living with modified Barthel Index (BI) ≥ 95. Patient must be living without requiring nursing care.
Qualifying imaging performed less than 2 hours prior to randomization.
Consent process completed as per national laws and regulation and the applicable ethics committee requirements.
Exclusion Criteria:
Treated with a tissue plasminogen activator (e.g., alteplase or tenecteplase) within 24 hours before randomization.
Determination by the treating physician, based on current treatment guidelines and medical evidence, that treatment with a plasminogen activator is indicated.
Large core of established infarction defined as ASPECTS 0-4.
Absent or poor collateral circulation on qualifying imaging (e.g. collateral score of 0 or 1).
Any intracranial hemorrhage on the qualifying imaging.
Planned use of an endovascular device not having approval or clearance by the relevant regulatory authority.
Endovascular thrombectomy procedure is completed as defined by the presence of TICI 2c/3 reperfusion or completion of groin / arterial closure.
Clinical history, past imaging or clinical judgment suggesting that the intracranial occlusion is chronic or there is suspected intracranial dissection such that there is a predicted lack of success with endovascular intervention.
Estimated or known weight > 120 kg (264 lbs).
Pregnancy/Lactation; female, with positive urine or serum beta human chorionic gonadotropin (β-hCG) test, or breastfeeding.
Known prior receipt of nerinetide for any reason, including prior enrolment in this ESCAPE-NEXT trial.
Severe known renal impairment defined as requiring renal replacement therapy (hemo- or peritoneal dialysis).
Severe or fatal comorbid illness that will prevent improvement or follow up.
Inability to complete follow-up treatment to Day 90.
Participation in another clinical trial investigating a drug, medical device, or a medical procedure in the 30 days preceding trial inclusion.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael D. Hill, MD MSc
Organizational Affiliation
Study Principal Investigator, University of Calgary
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Joseph's Hospital & Medical Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States
Facility Name
Providence Little Company of Mary Medical Center - Torrance
City
Torrance
State/Province
California
ZIP/Postal Code
90503
Country
United States
Facility Name
Swedish Medical Center
City
Englewood
State/Province
Colorado
ZIP/Postal Code
80113
Country
United States
Facility Name
Baptist Health Research Institute
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Facility Name
University of Miami, Jackson Memorial Hospital
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Grady Memorial Hospital
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30303
Country
United States
Facility Name
University of Maryland Medical Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
University of Massachusetts Medical School
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01655
Country
United States
Facility Name
Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
Facility Name
NYU Langone Hospital Brooklyn
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11220
Country
United States
Facility Name
The Ohio State University, Wexner Medical Center Neurological Surgery
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43203
Country
United States
Facility Name
Providence St. Vincent Medical Center
City
Portland
State/Province
Oregon
ZIP/Postal Code
97225
Country
United States
Facility Name
Abington Memorial Hospital
City
Abington
State/Province
Pennsylvania
ZIP/Postal Code
19001
Country
United States
Facility Name
UPMC Stroke Institute
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Rhode Island Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903-4923
Country
United States
Facility Name
Valley Baptist Medical Center - Harlingen
City
Harlingen
State/Province
Texas
ZIP/Postal Code
78550
Country
United States
Facility Name
Swedish Medical Center - Cherry Hill Campus
City
Seattle
State/Province
Washington
ZIP/Postal Code
98122
Country
United States
Facility Name
Royal Adelaide Hospital
City
Adelaide
Country
Australia
Facility Name
Princess Alexandra Hospital
City
Brisbane
Country
Australia
Facility Name
Monash Medical Centre
City
Clayton
Country
Australia
Facility Name
Gold Coast University Hospital
City
Gold Coast
Country
Australia
Facility Name
Fiona Stanley Hospital
City
Murdoch
Country
Australia
Facility Name
Sir Charles Gairdner Hospital
City
Nedlands
Country
Australia
Facility Name
John Hunter Hospital
City
Newcastle
Country
Australia
Facility Name
Royal Melbourne Hospital
City
Parkville
Country
Australia
Facility Name
Foothills Medical Centre - University of Calgary
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
University of Alberta Hospital
City
Edmonton
State/Province
Alberta
Country
Canada
Facility Name
Vancouver General Hospital
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
Health Sciences Centre
City
Winnipeg
State/Province
Manitoba
Country
Canada
Facility Name
Queen Elizabeth II Health Science Centre
City
Halifax
State/Province
Nova Scotia
Country
Canada
Facility Name
Hamilton Health Sciences
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
Kingston Health Sciences Centre
City
Kingston
State/Province
Ontario
Country
Canada
Facility Name
London Health Sciences Centre (LHSC)
City
London
State/Province
Ontario
Country
Canada
Facility Name
Ottawa Hospital Research Institute (OHRI)
City
Ottawa
State/Province
Ontario
Country
Canada
Facility Name
St. Michael's Hospital, Unity Health Toronto
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Sunnybrook Health Science Centre
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Toronto Western Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Montreal Neurological Institute and Hospital
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
University Hospital of Montreal
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
CHU de Quebec-Universite Laval
City
Quebec City
State/Province
Quebec
Country
Canada
Facility Name
Royal University Hospital
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
Facility Name
Universitätsklinikum RWTH Aachen
City
Aachen
Country
Germany
Facility Name
Klinikum Altenburger Land GmbH
City
Altenburg
Country
Germany
Facility Name
Universitätsklinikum Augsburg
City
Augsburg
Country
Germany
Facility Name
Universitätsklinikum Knappschaftskrankenhaus Bochum
City
Bochum
Country
Germany
Facility Name
Universitätsklinikum Bonn
City
Bonn
Country
Germany
Facility Name
Klinikum Dortmund gGmbH
City
Dortmund
Country
Germany
Facility Name
University of Dresden
City
Dresden
Country
Germany
Facility Name
Alfried-Krupp-Krankenhaus
City
Essen
Country
Germany
Facility Name
Universitätsklinikum Frankfurt
City
Frankfurt
Country
Germany
Facility Name
Universitätsklinikum Freiburg
City
Freiburg
Country
Germany
Facility Name
Göttingen University Hospital
City
Göttingen
Country
Germany
Facility Name
Universitätsklinikum Hamburg-Eppendorf
City
Hamburg
Country
Germany
Facility Name
Heidelberg University Hospital
City
Heidelberg
Country
Germany
Facility Name
University Hospital Schleswig-Holstein
City
Kiel
Country
Germany
Facility Name
Universitätsklinikum Leipzig - Klinik und Poliklinik für Neurologie
City
Leipzig
Country
Germany
Facility Name
Klinikum rechts der Isar Technical University of Munich
City
München
Country
Germany
Facility Name
LMU Klinikum München
City
München
Country
Germany
Facility Name
Universitätsklinikum Münster
City
Münster
Country
Germany
Facility Name
Nürnberg Hospital South Campus
City
Nürnberg
Country
Germany
Facility Name
Evangelisches Krankenhaus Oldenburg
City
Oldenburg
Country
Germany
Facility Name
Klinikum Stuttgart
City
Stuttgart
Country
Germany
Facility Name
Universitätsklinikum Tübingen
City
Tübingen
Country
Germany
Facility Name
Würzburg University Hospital
City
Würzburg
Country
Germany
Facility Name
Ospedale Maggiore di Bologna "Carlo Alberto Pizzardi"
City
Bologna
Country
Italy
Facility Name
Azienda Ospedaliero Universitaria Careggi
City
Firenze
Country
Italy
Facility Name
Ospedale Policlinico San Martino
City
Genoa
Country
Italy
Facility Name
ASST Grande Ospedale Metropolitano Niguarda
City
Milan
Country
Italy
Facility Name
Azienda Ospedaliera Antonio Cardarelli
City
Napoli
Country
Italy
Facility Name
Amsterdam UMC
City
Amsterdam
Country
Netherlands
Facility Name
Maastricht University Medical Center
City
Maastricht
Country
Netherlands
Facility Name
Erasmus University Medical Center
City
Rotterdam
Country
Netherlands
Facility Name
Oslo University Hospital Rikshospitalet
City
Oslo
Country
Norway
Facility Name
Oslo University Hospital Ulleval
City
Oslo
Country
Norway
Facility Name
Stavanger University Hospital
City
Stavanger
Country
Norway
Facility Name
University Hospital of North-Norway
City
Tromsø
Country
Norway
Facility Name
National Neuroscience Institute
City
Singapore
Country
Singapore
Facility Name
National University Hospital
City
Singapore
Country
Singapore
Facility Name
Kantonsspital Aarau
City
Aarau
Country
Switzerland
Facility Name
Universitätsspital Basel
City
Basel
Country
Switzerland
Facility Name
Universitatsklinik fur Neurologie, Inselspital
City
Bern
Country
Switzerland
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
We'll reach out to this number within 24 hrs